» Articles » PMID: 38466472

Role of Sirtuin 1 (SIRT1) in Regulation of Autophagy and Nuclear Factor-kappa Beta (NF-ĸβ) Pathways in Sorafenib-resistant Hepatocellular Carcinoma (HCC)

Overview
Date 2024 Mar 11
PMID 38466472
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) remains a major global health problem with high incidence and mortality. Diagnosis of HCC at late stages and tumour heterogeneity in patients with different genetic profiles are known factors that complicate the disease treatment. HCC therapy becomes even more challenging in patients with drug resistance such as resistance to sorafenib, which is a common drug used in HCC patients. Sorafenib resistance can further aggravate HCC by regulating various oncogenic pathways such as autophagy and nuclear factor-kappa Beta (NF-ĸβ) signalling. Sirtuin 1 (SIRT1), is a nicotinamide adenosine dinucleotide (NAD)-dependent histone deacetylases that regulates various metabolic and oncogenic events such as cell survival, apoptosis, autophagy, tumourigenesis, metastasis and drug resistance in various cancers, but its role in HCC, particularly in sorafenib resistance is underexplored. In this study, we generated sorafenib-resistant HepG2 and Huh-7 liver cancer cell models to investigate the role of SIRT1 and its effect on autophagy and nuclear factor-kappa Beta (NF-ĸβ) signalling pathways. Western blot analysis showed increased SIRT1, altered autophagy pathway and activated NF-ĸβ signalling in sorafenib-resistant cells. SIRT1-silenced HCC cells demonstrated down-regulated autophagy in both parental and chemoresistant cells. This may occur through the deacetylation of key autophagy molecules such as FOXO3, beclin 1, ATGs and LC3 by SIRT1, highlighting the role of SIRT1 in autophagy induction. Silencing of SIRT1 also resulted in activated NF-ĸβ signalling. This is because SIRT1 failed to deacetylate p65 subunit of NF-κB, translocate the NF-κB from nucleus to cytoplasm, and suppress NF-κB activity due to the silencing. Hence, the NF-κB transcriptional activity was restored. These findings summarize the role of SIRT1 in autophagy/NF-ĸβ regulatory axis, with a similar trend observed in both parental and sorafenib-resistant cells. The present work promotes a better understanding of the role of SIRT1 in autophagy and NF-ĸβ signalling in HCC and sorafenib-resistant HCC. As some key proteins in these pathways are potential therapeutic targets, a better understanding of SIRT1/autophagy/NF-ĸβ axis could further improve the therapeutic strategies against HCC.

Citing Articles

Involvement of SIRT1-mediated aging in liver diseases.

Zhang Y, Gong C, Tao L, Zhai J, Huang F, Zhang S Front Cell Dev Biol. 2025; 13:1548015.

PMID: 40052151 PMC: 11882576. DOI: 10.3389/fcell.2025.1548015.


IGF2BP3-dependent N6-methyladenosine modification of USP49 promotes carboplatin resistance in retinoblastoma by enhancing autophagy via regulating the stabilization of SIRT1.

Li L, Yang N, Sun J, Wei L, Gao Y Kaohsiung J Med Sci. 2024; 40(12):1043-1056.

PMID: 39497328 PMC: 11618494. DOI: 10.1002/kjm2.12902.


The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy.

Tang Y, Ju W, Liu Y, Deng Q Front Pharmacol. 2024; 15:1469830.

PMID: 39403142 PMC: 11471651. DOI: 10.3389/fphar.2024.1469830.


Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy.

Liu B, Liu L, Liu Y Front Immunol. 2024; 15:1450487.

PMID: 39315094 PMC: 11416969. DOI: 10.3389/fimmu.2024.1450487.

References
1.
Lohitesh K, Chowdhury R, Mukherjee S . Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018; 18:44. PMC: 5859782. DOI: 10.1186/s12935-018-0538-7. View

2.
Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View

3.
Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan F . SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene. 2013; 33(11):1468-74. DOI: 10.1038/onc.2013.88. View

4.
Ayob A, Ramasamy T . Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018; 25(1):20. PMC: 5838954. DOI: 10.1186/s12929-018-0426-4. View

5.
Wong M, Chan H, Aziz N, Ramasamy T, Bong J, Chng E . Interplay of autophagy and cancer stem cells in hepatocellular carcinoma. Mol Biol Rep. 2021; 48(4):3695-3717. DOI: 10.1007/s11033-021-06334-9. View